European Journal of Dermatology
MENUPemphigus and depression comorbidity: a case control study Volume 25, numéro 6, November-December 2015
Auteurs
3 Pediatric Dermatology Unit,
Department of Dermatology,
Tel Aviv Sourasky Medical Center,
6 Weizmann Street, Tel Aviv 64239, Israel
Department of Dermatology,
Tel Aviv Sourasky Medical Center,
6 Weizmann Street, Tel Aviv 64239, Israel
4 Department of Dermatology;
Centre national de référence des maladies génétiques à expression cutanée (Magec),
hôpital universitaire Necker-Enfants Malades;
APHP; université Paris Descartes - Sorbonne Paris Cité;
Institut Imagine,
Paris, France
Centre national de référence des maladies génétiques à expression cutanée (Magec),
hôpital universitaire Necker-Enfants Malades;
APHP; université Paris Descartes - Sorbonne Paris Cité;
Institut Imagine,
Paris, France
5 Siaal Research Center for Family Medicine and Primary Care,
Ben -Gurion University of the Negev,
Beer-Sheva, Israel
Ben -Gurion University of the Negev,
Beer-Sheva, Israel
* Reprints
a These authors contributed equally to the paper.
- Mots-clés : pemphigus, depression, corticoid therapy
- DOI : 10.1684/ejd.2015.2649
- Page(s) : 602-5
- Année de parution : 2015
Pemphigus is a relatively rare but severe autoimmune bullous disease, involving the skin and mucous membranes. The most common forms are pemphigus vulgaris (PV) and pemphigus foliaceus (PF). The overall incidence of the disease, which carries substantial morbidity and is potentially fatal, varies from 0.75 to 5 cases per million per year [1]. Pemphigus patients experience a decrease in quality of life (QOL) affecting physical, psychological and social aspects. While anxiety and depression have been [...]